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Background: The aim of this study was to compare the changes in primary (heroin use-related) and secondary
(depressive symptoms and quality of life, QOL) outcome indicators of 3-month methadone maintenance treatment
(MMT) between heroin users with and without HIV infection.
Methods: A total of 242 intravenous heroin-dependent individuals (30 with and 212 without HIV infection) receiving
MMT were recruited. Primary (severity of heroin dependence, harm caused by heroin use and current heroin use) and
secondary (depressive symptoms and QOL) outcome indicators were determined before and after receiving 3-month
MMT. Changes in primary and secondary outcome indicators between the two groups were compared using
mixed-model analysis.
Results: Heroin users both with and without HIV infection showed significant improvement in three primary
outcome indicators after 3-month MMT, and there was no difference in the changes of these primary outcome
indicators between the two groups. However, improvements in depressive symptoms and the physical domain of
QOL among HIV-infected heroin users were poorer than in those without HIV infection.
Conclusions: The results of this study indicated that heroin users with HIV infection did improve in the primary
but not the secondary outcomes after 3-month MMT.
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Heroin dependence is associated with poor physical and
mental health, unemployment and criminal activity and
has a chronic, relapsing course [1,2]. A recent study in
Taiwan found that the economic cost of heroin depend-
ence is huge, equal to 1.07 times the average gross
domestic product per capita in Taiwan [3]. Another
major problem associated with heroin use is the spread* Correspondence: wuhcmail@gmail.com; chfaye@cc.kmu.edu.tw
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unless otherwise stated.of blood-borne infections, such as human immunodefi-
ciency virus (HIV), among injecting drug users (IDUs).
In Taiwan, it was reported that only 2.1% of HIV-
positive individuals were IDUs in 2003 [4]. An outbreak
of HIV type 1 infection in Taiwan during 2003–2008
was caused by a new strain of HIV CRF07_BC [5]. It has
been estimated that IDUs contributed 38.5% of accumu-
lated HIV cases by the end of 2007 [6]. To control the
HIV epidemic among IDUs, harm reduction programs
were introduced in Taiwan for heroin users both with and
without HIV infection in 2005 [5]. Methadone mainten-
ance treatment (MMT) is a core component of the harm
reduction programs that have been recommended. MMT
has been available for heroin-dependent individuals
since the 1960s [7] and has been demonstrated to be aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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use, criminal behavior, risk of injection-related blood-
borne diseases and premature mortality among heroin
users [8]. After the implementation of MMT, the annual
percentage of new HIV infections from injected drug
use decreased dramatically [9], which further supports
the benefits of MMT in the control of blood-borne
infections among IDUs.
An important issue that requires further study is
whether the treatment outcomes of MMT are the same
between heroin users with and without HIV infection. A
cohort study showed that HIV-infected individuals have
higher rates of depression and heroin use disorder than
those not infected with HIV [10]. In a study of crack
users, HIV-positive users were more likely to be home-
less and unemployed during treatment than those nega-
tive for HIV [11]. Compared with HIV-negative heroin
users, heroin use has an immunosuppressive effect on
the central nervous system [12]. Heroin users with HIV
infection have a higher rate of comorbid infection with
hepatitis C virus than HIV-negative heroin users [13].
These study results show that HIV-infected heroin users
are a unique subgroup among heroin users. This high-
lights the importance of examining whether there are
differences in the treatment outcomes of MMT between
heroin users with and without HIV infection.
Whereas the severity of heroin dependence and harm
caused by heroin use and the occurrence of heroin use
are important outcome indicators of MMT, the levels of
depressive symptoms and quality of life (QOL) are also
important indicators. A 12-month follow-up study among
heroin users showed that more severe depressive symp-
toms at baseline can predict more injection-related health
problems and heroin use and less heroin abstinence
12 months later [14]. Therefore, effective treatment of
depressive symptoms in heroin users is an important issue
[15]. Regarding the effects of MMT on depressive symp-
toms, previous studies have reported that MMTcan lessen
the severity of depressive symptoms among heroin users
[16,17]. However, whether there is a different effect of
MMT on improving depressive symptoms between heroin
users with and without HIV infection remains unknown.
Depressive symptoms are common among people with
HIV infection [15]. In a nationally representative probabil-
ity sample of adults receiving care for HIV infection, there
is a 5–7% higher 12-month prevalence rate of depressive
disorders in individuals with HIV infection than in the
general population [18]. Further study is needed to exam-
ine whether there are differences in the effect of MMT on
improving depressive symptoms between heroin users
with and without HIV infection.
QOL has been defined by the World Health Organization
as a term of “individuals’ perceptions of their position in life
in the context of the culture and value systems in whichthey live and in relation to their goals, standards, expec-
tations and concerns” [19]. Research has found that
heroin users have a poorer QOL than those who do not
use heroin [20]. Meanwhile, individuals with HIV infec-
tion have to deal with a series of problems, such as
physical and psychological discomfort, economic stress,
social stigma and the fear of death, and thus QOL can
be compromised by HIV infection [21]. Whether there
is a different effect of MMT on improving the levels of
QOL between heroin users with and without HIV infec-
tion requires further study.
This study aimed to examine the changes in primary
(severity of heroin dependence, harm caused by heroin
use and current heroin use) and secondary (depressive
symptoms and QOL) outcome indicators during 3-month
MMT in heroin users with and without HIV infection.
The group differences in the changes of these outcome
indicators were also examined.
Methods
Research design and participants
This observational study recruited consecutive intraven-
ous heroin users with heroin dependence according to
the criteria of the DSM-IV-TR [22] who visited the
MMT clinics of three hospitals (two general hospitals
and one psychiatric hospital) in southern Taiwan from
March 2007 to July 2008. To achieve a desired power
higher than 0.8, the minimum sample size was 168
[23,24]. A total of 242 heroin users agreed to participate
in this 3-month follow-up study. All participants had
not received methadone previously. All participants re-
ceived an HIV serostatus test by ELISA, and if the
screening test was positive, western blot was used as a
confirmatory test. If the result was positive, participants
were confirmed as HIV-positive. Of 242 participants, 30
were HIV-positive and 212 were HIV-negative. All HIV-
positive participants were at the clinical latency stage
and were not on any antiretroviral therapy. Regarding
methadone dosage, doctors adjusted dosages to ad-
equately reduce craving and opioid withdrawal symp-
toms in the first month of treatment for both groups.
Then participants continued taking their stabilization
dose through to the end of this study. They underwent
intake interviews to collect baseline data before receiving
MMT and were evaluated again after receiving 3-month
MMT. At each evaluation, participants were interviewed
face to face by research assistants who were blind to the
baseline data, to collect the outcomes at the follow-up
points. The study protocol was approved by the Institu-
tional Review Board of Kaohsiung Medical University.
Survey instruments
At each interview, the instruments described below were
used to collect data.
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(SDS[Ch])
The five-item SDS[Ch] was used to evaluate participants’
severity of heroin use [25,26]. Each item is scored on a
four-point scale (scored 0 to 3). The total SDS score
ranges from 0 to 15, with higher scores indicating a
greater degree of dependence. Cronbach’s alpha of the
SDS[Ch] in this study was 0.78.
Current heroin use
Participants reported whether they had used heroin be-
fore intake and during the last month of the study. Each
participant had urine tests at the end of the study.
Current heroin use at baseline and at the 3-month
follow-up interview was determined by either self-
reported use in the last month or by a positive heroin
confirmation urine test at clinic visits.
Questionnaire for harm of heroin use (Q-HOU)
This seven-item, four-point questionnaire assesses the
subjective harmful experiences caused by heroin use
during the past 3 months, including those related to
physical and mental health, family relationships, inter-
personal relationships, legal problems, academic or oc-
cupational performance, and economic hardship. For
example, participants were asked, “Have you ever experi-
enced physical problems due to heroin use during the
past 3 months?” The 1-week test-retest reliability ranged
from 0.394 (p < 0.05) to 0.742 (p < 0.001). Cronbach’s
alpha of the Q-HOU in this study was 0.93. Higher total
scores on the Q-HOU indicate that individuals are
experiencing more severe harm owing to heroin use.
Chinese version of the center for epidemiological studies
depression scale (CES-D)
The Chinese version of the CES-D has been used to study
depressive symptoms in Taiwan for many years [27].
Possible total scores on the CES-D range from 0 to 60,
with higher scores indicating more severe depressive
symptoms. The internal consistency (Cronbach’s alpha) of
the Chinese version of the CES-D in this study was 0.86.
Taiwan brief version of the world health organization
quality of life instrument (WHOQOL-BREF)
The Taiwan version of the WHOQOL-BREF includes 28
items, consisting of 26 standard items from the original
WHOQOL-BREF and two Taiwanese national items
[28]. This is a self-administered questionnaire that
assesses the levels of QOL in the health, psychological,
environment and social relationship domains. The in-
ternal consistency coefficients (Cronbach’s alpha) of the
Taiwan version of the WHOQOL-BREF ranged from
0.70 to 0.77 for the four domains. The test-retest reli-
ability coefficients with intervals of 2 to 4 weeks rangedfrom 0.41 to 0.79 at the item/facet level and 0.76 to 0.80
at the domain level (all p < 0.01). The content validity
coefficients were in the range of 0.53 to 0.78 for item-
domain correlations and 0.51 to 0.64 for inter-domain
correlations (all p < 0.01) [28].
Attendance rate of MMT
The attendance rate of MMT was determined by the days
on which methadone was taken during the 3-month MMT.
Statistical analysis
Data analysis was performed using the Statistical Package
for the Social Sciences (SPSS) 20.0 software. Baseline
characteristics of the participants were compared
between participants with and without HIV infection
using the χ2 test and t-test. Changes in the severity of
heroin dependence, harm caused by heroin use and
depressive symptoms and the levels of QOL during the
3-month MMT were examined separately by the paired
t-test in the two groups of participants. Change in status
of current heroin use before and after the 3-month
MMT was examined separately by the related-samples
McNemar test in the two groups of participants. Mean-
while, we used generalized linear mixed-model analysis
to examine group differences in the changes in heroin
dependence, harm caused by heroin use, status of
current heroin use, depressive symptoms and QOL
during 3-month MMT between heroin users with and
without HIV infection. Mixed-model analysis is useful
in settings where unbalanced measurements are made
of the same statistical units [29]. In the mixed-model
analysis, changes in the outcome indicators were used
as dependent variables, the group variable was used as
an independent variable and sex, age, education level
and attendance rate of MMT were used as control vari-
ables. We used the 0.05 significance level for all inferen-
tial statistical procedures.
Results
Of the 30 participants with HIV infection, five (16.67%)
were female and 25 (83.33%) were male. Of the 212 par-
ticipants without HIV infection, 25 (11.79%) were female
and 187 (88.21%) were male. There was no significant
sex difference between the two groups. The mean age
(standard deviation, SD) was 37.20 years (7.48 years) and
37.73 years (7.29 years) in participants with and without
HIV infection, respectively. The mean duration of edu-
cation (SD) was 9.84 years (2.37 years) and 9.25 years
(2.14 years) in participants with and without HIV infec-
tion, respectively. There were no significant differences
in sex, age and duration of education between par-
ticipants with and without HIV infection. The severities
of heroin dependence, harm from heroin use and de-
pressive symptoms, the levels of QOL, and the
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ticipants both with and without HIV infection are
shown in Table 1. There were no significant differences
in these indicators at baseline between participants with
and without HIV infection.
Both groups reported heroin use at the intake inter-
view. Rates of self-reported heroin use during the last
month of the study were 66.67% and 61.32% for HIV-
positive and HIV-negative participants, respectively. The
urine-positive rates for the HIV and non-HIV groups
were 73.33% and 66.51%, respectively. Both the rate of
self-reported heroin use and the urine-positive rate did
not differ between the two groups. The difference in
methadone dosages (SD) was not significant, with 52.33
(20.03) (mg/day) and 57.56 (30.12) (mg/day) for the HIV
and non-HIV groups, respectively.
Results of the comparison between treatment outcomes
before and after MMT in heroin users with and without
HIV infection are shown in Table 1. In participants without
HIV infection, severity of heroin dependence, harm caused
by heroin use and depressive symptoms and the proportion
rate of current heroin use decreased significantly during
the 3-month MMT; additionally, all four domains of QOL
improved significantly during the 3-month MMT. In par-
ticipants with HIV infection, the severity of heroin depend-
ence and harm caused by heroin use were significantly
improved after the 3-month MMT; the proportion rate of
heroin use also significantly decreased. However, the sever-
ity of depressive symptoms and the levels of all four do-
mains of QOL did not significantly improve in participants
with HIV infection after 3-month MMT.Table 1 Comparison of treatment outcomes before and after
Heroin users with
HIV infection
Mean (SD) or n (%)
Baseline 3 months after
receiving MMT
Severity of heroin dependence
on the SDS[Ch]
9.10 (2.89) 5.60 (2.57)
Severity of harm caused by
heroin use
14.77 (5.29) 7.00 (6.31)
Current heroin use 30 (100) 24 (80)
Severity of depressive symptoms
on the CES-D
20.48 (9.11) 19.60 (10.45)
Level of QOL on the
WHOQOL-BREF
Physical health 22.93 (4.60) 23.27 (4.87)
Mental health 16.11 (3.11) 17.73 (4.10)
Social 12.86 (2.88) 12.97 (2.63)
Environmental 27.43 (5.41) 29.10 (5.45)
Abbreviations: CES-D Center for Epidemiological Studies Depression Scale, MMT met
of the Severity of Dependence Scale, WHOQOL-BREF Taiwan brief version of the Wo
McNemar test.Results of the comparison of changes in heroin de-
pendence, harm caused by heroin use, current heroin
use, depressive symptoms and QOL during the 3-month
MMT between heroin users with and without HIV in-
fection using mixed-model analysis are shown in Tables 2
and 3. The results indicated that after controlling for
sex, age, years of education and attendance rates, there
were no significant differences in the changes in severity
of heroin dependence and harm caused by heroin use
and the proportion rate of current heroin use during the
3-month MMT between heroin users with and without
HIV infection. However, heroin users without HIV
infection showed greater improvement in the severity
of depressive symptoms than those with HIV infection
during 3-month MMT. Regarding QOL, heroin users
without HIV infection had greater improvement in the
physical health domain of QOL than those with HIV
infection. There were no significant differences in the
changes in other domains of QOL during 3-month
MMT between heroin users with and without HIV
infection.
Discussion
This study determined the changes in severity of heroin
dependence, harm caused by heroin use, current heroin
use, depressive level and QOL during 3-month MMT in
heroin users with and without HIV infection. We ob-
served that in heroin users both with and without HIV
infection, three primary outcome indicators related to
heroin use improved significantly after 3-month MMT,
namely the severity of dependence and harm caused byMMT in heroin users with and without HIV infection
p Heroin users without p
HIV infection
Mean (SD) or n (%)
Baseline 3 months after
receiving MMT
<0.0001a 9.27 (2.91) 6.30 (2.36) <0.0001a
<0.0001a 13.69 (4.98) 8.34 (6.31) <0.0001a
<0.0001b 212 (100) 153 (72.17) <0.0001b
.856a 21.75 (10.48) 15.73 (8.92) <0.0001a
.602a 21.47 (4.33) 24.05 (4.45) <0.0001a
.284a 16.89 (3.90) 18.88 (4.13) <0.0001a
.823a 12.03 (2.48) 12.83 (2.75) <0.0001a
.063a 27.15 (5.28) 29.39 (6.8) <0.0001a
hadone maintenance treatment, QOL quality of life, SDS[Ch] The Chinese version
rld Health Organization Quality of Life instrument. a: paired t-test; b:
Table 2 Group comparisons of the changes in heroin dependence, harm caused by heroin use and current heroin use:
mixed-model analysis
Severity of heroin dependence Severity of harm caused by heroin use Current heroin use
Coefficient p Coefficient p OR (95% CI of OR) p
HIV positive serostatus −0.371 .613 −2.531 .061 1.430 (0.517-3.952) .489
Sex: male −0.931 .221 0.225 .870 1.163 (0.431-3.134) .765
Age −0.01 .786 −0.181 .004 0.985 (0.947-1.025) .468
Education level −0.058 .625 −0.199 .307 1.090 (0.966-1.231) .161
Attending rate −5.050 .002 −2.120 .460 0.034 (0.002-0.428) .013
Abbreviations: CI confidence interval, OR odds ratio.
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studies showed that MMT can reduce heroin use
[30,31]. However, these studies did not analyze the effect
of MMT on reducing heroin use in individuals who were
infected with HIV. We further compared the changes in
these three heroin use-related outcome indicators be-
tween heroin users with and without HIV infection and
found that MMT has similar effects in both groups.
Therefore, the results of this study support that MMT
can reduce heroin use and the harm caused by heroin
use, regardless of HIV serostatus.
Nevertheless, we found that the effects of MMT on
improving depressive symptoms and QOL are different
between heroin users with and without HIV infection. In
contrast to heroin users who are negative for HIV, the
severity of depressive symptoms did not significantly im-
prove after 3-month MMT in the HIV-infected heroin
users. Comparison of the changes in depressive symp-
toms also showed that heroin users without HIV infec-
tion had greater improvement in depressive symptoms
than HIV-infected users. Tsao et al. showed that people
with HIV infection experience more pain and distress
than the general population [32]. Pain is not only a risk
factor for developing depressive symptoms [33] but can
also be a depressive symptom [34,35]. In addition, dis-
tress [36], stigma towards people with HIV [37], and a
high virus load are associated with severity of depressive
symptoms [38,39]. In addition, in the early stages of HIV
infection, a reduced level of serotonin in the brain may





Coefficient p Coefficient p
HIV positive serostatus 5.588 .005 −2.136 .016
Sex: male −5.414 .009 1.150 .205
Age 0.144 .122 −0.018 .657
Education −0.055 .850 −0.003 .981
Attending rate −1.952 .648 3.942 .038These findings of previous studies have supported that
heroin users with HIV infection may be more vulnerable
to the development of depressive symptoms than those
without HIV infection, and have partially accounted for
the difference in the effect of MMT on improving de-
pressive symptoms between heroin users with and with-
out HIV infection. The results of our study indicated
that heroin users with HIV infection may need interven-
tions in addition to MMT to improve their depressive
symptoms. Pyne et al. reviewed previous studies on the
care of patients with HIV infection and suggested that
antidepressants may improve depressive symptoms in
HIV-positive patients [41]. Psychological intervention,
particularly intervention with a cognitive-behavioral
component, has been shown to be effective in treating
depressive symptoms among individuals with HIV infec-
tion who are drug users [15,42]. Research has also shown
that depressive symptoms in HIV-infected individuals re-
quire multicomponent interventions [43]. Comprehensive
treatments integrating pharmacological and psychosocial
interventions may be essential to improve depressive
symptoms in heroin users with HIV infection.
We found that heroin users without HIV infection also
had greater improvement in the physical health domain
of QOL than those with HIV infection after controlling
for age, sex, education level, and attendance rate of
MMT. Previous studies have found that HIV-positive in-
dividuals have low rates of coordinated and continuous
health care use [44] but disproportionately high hospi-
talization rates [45]. Furthermore, health care utilizationms and quality of life: mixed-model analysis
psychological social environmental
Coefficient p Coefficient p Coefficient p
−1.245 .110 −0.699 .172 −0.516 .615
2.255 .005 0.999 .057 1.441 .171
0.007 .835 0.028 .232 −0.032 .504
−0.004 .974 0.008 .931 0.038 .796
2.221 .181 1.706 .118 2.385 .277
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drugs than for those who do not [46]. HIV-positive indi-
viduals reporting crack or cocaine use were also less
likely to positively perceive quality of health care than
those who were not substance abusers [47]. The results
of this and previous studies indicate that the physical
domain of QOL in HIV-infected heroin users requires
integrated treatment programs, for example cooperation
between professionals in the fields of addiction and in-
fectious disease.
There are some limitations to this study that should
be addressed. First, imbalance in the sample sizes of the
groups of heroin users with and without HIV infection
may limit the inferences of our findings. However, we
used mixed-model analysis, an effective method in
unbalanced samples, to deal with this problem [48]. Sec-
ond, the rates of self-reported heroin use in this study
were lower than the urine-positive rates in both groups.
Therefore, current heroin use was determined based on
self-reporting or a urine test to avoid underestimating
heroin use; the literature has shown that self-reporting
among drug users in research settings has acceptable
reliability and validity [49,50]. Third, the follow-up
period of this study was 3 months. Further study is
needed to examine whether treatment outcomes differ
between heroin users with and without HIV infection if
the follow-up period is longer.
In conclusion, this study found that the primary out-
comes regarding heroin use are improved during 3-month
MMT in heroin users both with and without HIV infec-
tion, whereas poorer improvements in depressive symp-
toms and the physical domain of QOL were found in
HIV-infected heroin users compared with those without
HIV infection. Owing to the high prevalence rate of HIV-
positive serostatus among heroin users, clinicians should
take mood and QOL into consideration and incorporate
multicomponent treatment programs when treating her-
oin users. Connock et al. showed that adjunctive psycho-
social interventions may enhance the treatment outcomes
of MMT [51]. Archana et al. suggested that simultaneous
use of evidence-based substance use treatment and psychi-
atric care is needed to improve health outcomes in heroin
users with HIV infection [52]. How to best help HIV-
infected heroin users to improve their treatment out-
comes, especially depressive symptoms and the physical
domain of QOL, requires further study.
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